Evidence map›Paper›PMID 17981924›Full record

Trial reportClinical chemistry2008

Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.

Allan J Barnes, Michael L Smith, Sherri L Kacinko, Eugene W Schwilke, Edward J Cone, Eric T Moolchan, Marilyn A Huestis

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Clinical chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05971043 (Skin Disorders in Patients Using Methamphetamine), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05971043 unknown statusnot on this mapstarted 2023, after this paper: background citation

Skin Disorders in Patients Using Methamphetamine

TypeobservationalSponsorAssiut UniversityRan2023 to 2024Enrolled500ConditionsMethamphetamine Abuse
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Allan J BarnesChemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Michael L Smith
Sherri L Kacinko
Eugene W Schwilke
Edward J Cone
Eric T Moolchan
Marilyn A Huestis
National Institute on Drug Abuse · USNational Institutes of Health · USArmed Forces Institute of Pathology · USJohns Hopkins University · US

Funding

Detection Of Drugs Of Abuse In Alternative Biological Fluids And TissuesZIADA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$3.9M
Detection Of Drugs Of Abuse In Biological Fluids/TissuesZ01DA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HUESTIS, MARILYN · 1998 to 2008
$956k
PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS OF ABUSEZ01DA000414 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HUESTIS, MARILYN A · 1998 to 2008
$373k
Intramural NIH HHS Z01 DA000412Intramural NIH HHS Z01 DA000414
6 · The paper itself

Abstract

backgroundUnderstanding methamphetamine (MAMP) and amphetamine (AMP) excretion in sweat is important for interpreting sweat and hair testing results in judicial, workplace, and drug treatment settings.

methodsParticipants (n = 8) received 4 10-mg (low) oral doses of sustained-release S-(+)-MAMP HCl (d-MAMP HCl) within 1 week in a double-blind, institutional review board-approved study. Five participants also received 4 20-mg (high) doses 3 weeks later. PharmChek sweat patches (n = 682) were worn for periods of 2 h to 1 week during and up to 3 weeks after dosing. The mass of MAMP and AMP in each patch was measured by GC-MS, with a limit of quantification of 2.5 ng/patch.

resultsMAMP was measurable in sweat within 2 h of dosing. After low and high doses, 92.9% and 62.5% of weekly sweat patches were positive, with a median (range) MAMP of 63.0 (16.8-175) and 307 (199-607) ng MAMP/patch, respectively; AMP values were 15.5 (6.5-40.5) and 53.8 (34.0-83.4) ng AMP/patch. Patches applied 2 weeks after the drug administration week had no measurable MAMP following the low doses, and only 1 positive result following the high doses. Using criteria proposed by the Substance Abuse Mental Health Services Administration, 85.7% (low) and 62.5% (high) weekly sweat patches from the dosing week were positive for MAMP, and all patches applied after the dosing week were negative.

conclusionsThese data characterize the excretion of MAMP and AMP after controlled MAMP administration and provide a framework for interpretation of MAMP sweat test results in clinical and forensic settings.

Indexed as

Administration, OralAdultAmphetamineDelayed-Action PreparationsDouble-Blind MethodFemaleHumansMaleMethamphetamineSubstance Abuse DetectionSweatAmphetamineDelayed-Action PreparationsMethamphetamine

Identifiers

PMID17981924
PMCPMC2714868
OpenAlexW2157640370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.